We identified genes that were differentially expressed between spontaneously hypertensive rats (SHR) and Wistar-Kyoto rats (WKY) using cDNA microarray analysis, and analyzed the correlation between these genes and hypertension. Twenty four genes were found to be up-regulated and 20 were down-regulated in SHR. 
Introduction
Hypertension is a major risk factor for cardiovascular morbidity and mortality. Due to its complex nature as a polygenic, heterogeneous and multifactorial disease, effective therapies have remained elusive. The nature of this complex disease makes it difficult to directly identify contributing genes in human beings (1, 2) . Genetically hypertensive rat models provide a simple and accessible model for studying spontaneously hypertensive and Wistar-Kyoto rats using cDNA microarray analysis, and attempted to identify the genes that are expressed differently in these two strains. Because renal transplantation experiments have suggested that primary genetic defects may reside in the kidneys of SHR (5, 6) , it was expected that some of the genes involved in the pathogenesis or maintenance of hypertension in SHR might be differentially expressed between the kidneys of the two strains. Such differential expression may be due to some nonpathological strain difference, may be a secondary compensatory phenomenon caused by hypertension, or may be a primary cause of hypertension. To discriminate among these possibilities, we assessed the effects of antihypertensive therapy and performed an F2 cosegregation analysis for several genes that were found to be differentially expressed.
Materials and Methods

Microarray Analysis
RNA was extracted according to the method of Chomczynski and Sacchi (7) from the kidneys of 10-week-old SHR and WKY (Hoshino-jikken-doubutu, Hamamatsu, Japan). The RNA probe samples were processed as recommended by Affymetrix Inc. (Santa Clara, USA). Briefly, cDNA was synthesized from 2.0 mg of purified poly (A) RNA using the Superscript Choice System (Invitrogen, Carlsbad, USA) with an oligo-dT primer containing a T7 promoter sequence (5 -GGCCAGTGAATTGTAATACGACTCACTATAGGGAG GCGG-(T)24-3 ) (Amersham Pharmacia Biotech, Buckinghamshire, UK). This cDNA was then used to perform in vitro transcription with a T7 RNA polymerase incorporating biotin-labeled nucleotides using the BioArray RNA Transcript Labeling Kit (Enzo Diagnostics, Farmingdale, USA). Biotinlabeled cRNA probe samples were purified by column cleanup using an RNeasy mini kit (QIAGEN, Hilden, Germany). After quantifying the cRNA concentration, cRNA was fragmented and hybridized at 45˚C overnight to an Affymetrix rat genome U34A array containing 8799 probe array sets. The arrays were washed, stained, and scanned using a Fluidics Station and microarray scanner, which are components of the Affymetrix GeneChip Instrument System. Finally, the results were analyzed using GeneChip analysis software (Ver. 4.0; Affymetrix), which gave the fold-change and the average difference change between the hybridization intensity of the SHR and WKY samples. Three independent experiments were performed, and results that were confirmed by at least two experiments were considered in the 
Probes for northern blot analysis were synthesized by RT-PCR using the primers listed above. 
Probe Synthesis and Northern Blot Analysis
To synthesize specific probes for each gene, partial cDNA fragments were synthesized by RT-PCR using total RNA derived from WKY kidneys. PCR products were subcloned using TOPO-TA cloning kits (Invitrogen). The sense and antisense primers are listed in Table 1 .
Isolated total RNA was electrophoresed in 1% agarose/ formaldehyde gel (10 µg/lane) and transferred onto nylon membranes. Probes were labeled with Fluorescein-12-UTP (NEN Life Science Products, Boston, USA). Hybridization and detection procedures using Antifluorescein-HRP Conjugate (NEN Life Science Products) and Renaissance Nucleic Acid Chemiluminescence Reagent (NEN Life Science Products) were performed according to the manufacturer's instructions. Chemiluminescence was detected using an LAS-1000 plus image analyzer (Fuji Film, Tokyo, Japan).
Experimental Animals and Genetic Crosses
The F2 rats used in the present study were prepared as described previously (8, 9) . Briefly, male SHR/Hos rats were mated with female WKY/Hos rats (Sankyo Co., Ltd., Shizuoka, Japan) to produce F1 rats, and male F1 and female F1 rats were then intercrossed to produce an F2 population consisting of 105 male rats. At 15 weeks of age, a catheter was implanted into the abdominal aorta via a femoral artery. SBP, DBP, and heart rate were measured three times at 24 h after catheterization with rats in a conscious state.
Eight-week-old male SHR were treated orally once a day for two weeks with either vehicle (n 6), enalapril (30 mg/kg) (n 6), or hydralazine (30 mg/kg) (n 6). RNA was extracted from the kidneys and subjected to microarray analysis as described above. Blood pressure in these rats was assessed by the tail-cuff method to verify the antihypertensive effects of these drugs.
Genetic differences between SHR and WKY were screened and genotyped by either sequencing or microsatellite marker typing. The PCR primers used for genotyping are listed in Table 2 . 
Polymorphisms of the candidate genes were determined by direct sequencing or electrophenesis size fractonation of PCR produces using primers listed above. Abbreviations are the same as in Table 1 . SSLP, simple sequence length polymorphism; SNP, single nucleotide polymorphism; PSA1, typing primer set name associated with SA gene (GenBank accession number U04637, ref.14). D14Rat64 and D7Mit26, SSLP typing marker (Research Genetics). SOD3 and ELA1 genes were neighbor to or linked with D14Rat64 and D7Mit26, respectively (RATMAP homepage, http://ratmap.gen.gu.se). The microarray analysis showed 24 probe sets were increased, 20 probe sets were decreased in SHR. Probe sets were listed in descending manner in Expression Change. Gene Descriptions and GenBank Accession Number were according to Affymerix GeneChip Suite software. Expression Change and Fold Change show difference change and fold change of expression intensities of these genes between SHR and WKY, respectively. Genes served to F2 cosegregation analysis were noted with . HSP70, heat shock protein 70; ADH, alcohol dehydrogenase; RBP4, retionol-binding protein; DBP, vitamin D binding protein; IDI1, isopentenyl diphosphatedimethylallyl diphosphate isomerase, SOD3, superoxide disannlass; GST, glutathione S-transferase; NNE, non-neuronal enolase.
The present study was conducted in accordance with current guidelines for the care and use of experimental animals of the National Cardiovascular Center.
Quantitative Trait Loci (QTL) Analysis
Since the human MCT1 and GST Y(b) genes (1p13.2) are homologous to a chromosomal region on rat chromosome 2, we genotyped the microsatellite markers on chromosome 2 to elucidate these gene loci. The chromosomal locations of other genes were determined by the same strategy. Genotyping was performed by PCR amplification of DNA around the polymorphic microsatellite markers from the total genomic DNA of the F2 rats using appropriate PCR primer pairs (custom-made by Amersham Pharmacia Biotechnology), based on information from Research Genetics. Map Manager QT (10) was used for the QTL analysis at this locus.
Results
Selection of Differentially Expressed Genes
The microarray analysis revealed 4,268 genes expressed in SHR vs. 4,216 genes in WKY. Table 3 shows all of the genes that showed increased or decreased expression in at least two experiments. Twenty-four genes were up-regulated and 20 were down-regulated in SHR.
We selected genes for which there was a greater than 2-fold difference in expression between SHR and WKY, and for which the difference in expression intensity was more than 1,000 (not including the EST clone) (Table 4) . Thus, 6 genes that were up-regulated and 5 genes that were downregulated in SHR were subjected to further analyses. The differential expression of these 11 genes was confirmed by Northern blot analysis (Fig. 1) .
F2 Cosegregation Analysis
We identified genetic polymorphisms of these 11 genes (Table 2) and performed a cosegregation analysis of these polymorphisms with blood pressure in an F2 population (Table 4) . A significant association with diastolic blood pressure was observed for the genes for the monocarboxylate transporter (MCT1) (11) and glutathione S-transferase Y(b) subunit (12) . Since these 2 genes were located near each other on rat chromosome 2, we performed a QTL analysis with several microsatellite markers in this region (Fig. 2) . A significant QTL for diastolic blood pressure existed in this region, but was distinct from these two genes. We did not analyze the SAH locus since this locus has been analyzed in detail by several researchers. We concluded that none of the 11 genes analyzed caused hypertension in SHR.
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Effects of Antihypertensive Treatment
Because the differential expression of genes in SHR might be a compensatory mechanism for high blood pressure, we analyzed the effects of antihypertensive treatment on the expression levels of these 11 genes. Antihypertensive treatment with either enalapril ( 50 mmHg) or hydralazine ( 70 mmHg) significantly decreased blood pressure in SHR compared to that in the vehicle-administered controls after two weeks of treatment. However, only the expression of Hsp70 was modulated by antihypertensive treatment. The expression level of Hsp 70 was upregulated 3-fold with hydralazine, but not with enalapril.
Discussion
Although many studies have identified QTLs for blood pressure in SHR (13-21), we are still unable to identify specific genes that contribute to hypertension in SHR. In this study, we attempted to identify the genes responsible for hypertension by means of an oligonucleotide microarray system. The microarray system has greatly enhanced the process of gene expression analysis by allowing easy screening of differen- Genes with a greater-than-2-fold difference and whose expression level was more than 1,000 in at least one of the strain were listed as candidate genes. Chromosomal locations from database both in rat and human of these genes were shown. F2 rats cosegregation ANOVA analysis showed significant association with blood pressure for SLC16A1 and GSTM4. p 0.05. Antihypertensive treatment to SHR only effects on the expression level of HSPA1A(HSP70), up-regurated 2.9-fold with hydralazine. ND, not determined; SBP, systolic blood pressure; DBP, diastolic blood pressure; NC, not changed.
tially expressed genes. In fact, through a combination of microarray and QTL analyses, CD36 was identified as one of the genes responsible for SHR defects in glucose and fatty acid metabolism (22) . From the genes obtained through microarray analysis, we selected 11 candidate genes on the basis of marked differential expression between SHR and WKY, and subjected these genes to a genetic cosegregation analysis (Table 3) . Polymorphisms of the MCT1 and GST Y(b) subunit genes were significantly cosegregated with blood pressure; however, the peak LOD score was out of the loci of these genes (Fig. 2) . We therefore concluded that these differentially expressed genes do not cause hypertension in SHR. Moreover, the marked differential expression of these genes, with the exception of Hsp70, does not seem to compensate for high blood pressure, since antihypertensive treatment with either enalapril or hydralazine did not modify the expression levels of these genes.
Hsp70 has been shown to be induced by catecholamines (23) . Thus, the upregulation of Hsp70 in SHR may be due to higher sympathetic activity in SHR, and the induction of Hsp70 by hydralazine may be due to the compensatory upregulation of sympathetic tone by hydralazine. In this sense, only Hsp70 was shown to be related to hypertension in SHR. We were unable to associate the other 10 genes with blood pressure regulation. Thus, the identification of differentially expressed genes is not an efficient method for selecting candidate genes for hypertension in the SHR-WKY system.
There are several limitations to the present study. Although blood pressure was measured directly, telemetric monitoring of blood pressure might have been preferable. Furthermore, the number of F2 rats in the present study (105) may have been too small for precise detection of the QTLs for blood pressure. Ideally, moreover, the present analysis would have been extended to genes with less marked differences and genes that are differentially expressed in other tissues. These limitations need to be taken into account in future studies.
